INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

PRESCRIBING INFORMATION

Bramitob® (tobramycin): Concentrated on tolerability and safety

Bramitob® offers a favourable safety profile

  • 98% adherence rates across Phase II/III clinical trials1,2
  • In a placebo-controlled trial, generally well-tolerated, with a low incidence of hearing disturbance and bronchospasm1

 

REPORTED ADVERSE EVENTS3*

 


*Data derived from 4 controlled clinical trials and 1 uncontrolled clinical trial with Bramitob, n=565
Common (≥1/100 and <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 and <1000); very rare (<1/10,000)

For the full list of Adverse Events, please see the UK Summary of Product Characteristics or the Ireland Summary of Product Characteristics.

HIGH RATES OF ADHERENCE ACROSS CLINICAL TRIALS1,2


1. Chuchalin A, et al. Pediatr Drugs. 2007; 9 Suppl. 1:21-31.
2. Lenoir G, et al. Pediatr Drugs. 2007;9 Suppl. 1:11-20.
3. Bramitob® Summary of Product Characteristics. Available online at https://www.medicines.org.uk/emc/medicine/21427. Accessed March 2018.